TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage...
SINGAPORE and BETHESDA, Md., May 30, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company...
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the...
New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May...
PLEASANTON, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a leading CPAP alternative for the...
CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company,...
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Selected for Oral PresentationStudy done in the CMT1A mouse modelSupported by the CMT Research FoundationMADRID, Spain and BOSTON, May 30,...
Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases...
Expect to report initial clinical data for FLT201 in Gaucher disease in third quarter of 2023 FLT201 granted ILAP designation,...
Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity...
INSIDE INFORMATION Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024...
Priority Review Granted withPrescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an...
AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
Daix (France), Long Island City (New York, United States), May 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA),...
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering...
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering...
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with...